GIP and Hepatic fibrosis: Phase 2 trials with liver-directed mechanisms (Efruxifermin, Pegozafermin) that target FGF-21 or weight-loss combinations of GLP-1/GIP/Glucagon (Tirzepatide, Survodutide) have shown improvement in liver fibrosis and are currently in phase 3 investigations [17,18,19,20].